<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903044</url>
  </required_header>
  <id_info>
    <org_study_id>ICMI_ 404732/2012-7</org_study_id>
    <nct_id>NCT01903044</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating</brief_title>
  <official_title>Multicentric Study of the Autologous Bone Marrow-derived Mononuclear Cells Injection for Treatment of the Patients With Critical Lower Extremity Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontifícia Universidade Católica do Paraná</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Moléstias Cardiovasculares de São José do Rio Preto, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sao Rafael</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Geral Nacional Enrique Cabrera, Cuba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Hematología e Inmunología, Cuba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação Araucária</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontifícia Universidade Católica do Paraná</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether autologous bone marrow-derived stem cells&#xD;
      are effective in the treatment of lower extremity ischemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critical limb ischemia (CLI) is a debilitating and disabling disease. Symptoms include pain&#xD;
      at rest, loss of tissue integrity, distal amputations and have a major impact on the quality&#xD;
      of life. Despite recent advances in surgical vascular procedures, a large number of patients&#xD;
      (approximately 40%) are not eligible for these revascularization procedures. New strategies&#xD;
      for revascularization need to be explored. Besides, in some cases results of such&#xD;
      interventions do not give desirable effect, search of new methods of treatment therefore is&#xD;
      necessary. Recent evidence indicates that bone marrow-derived mononuclear cells (BM-MNC) are&#xD;
      a potential new therapeutic target.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound healing (wound size, wound stage) - monitoring the healing of trophic lesions</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome classification</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Improvement of symptoms, functional capacity, exercises tolerance assessed by change in Rutherford scale of CLI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and analgesics use</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome</measure>
    <time_frame>3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the coronary and collateral circulation.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without amputation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lower Extremity Ischemia</condition>
  <condition>Leg Ulcer</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Diabetic Foot</condition>
  <condition>Gangrene</condition>
  <arm_group>
    <arm_group_label>BM-MNC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of autologous bone marrow-derived mononuclear cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BM-MNC injection</intervention_name>
    <description>BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles</description>
    <arm_group_label>BM-MNC injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Critical lower limb ischemia, defined as ischemic pain at rest and / or the presence&#xD;
             of minor tissue loss, with the possibility of healing.&#xD;
&#xD;
          -  Failure of conventional medical treatment and attempts to open or percutaneous&#xD;
             revascularization before, with an observation period of two months after the last&#xD;
             attempt at revascularization.&#xD;
&#xD;
          -  Patients considered at high risk for new revascularization procedure by at least two&#xD;
             independent observers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expected life span less than six months&#xD;
&#xD;
          -  Large tissue loss in the ischemic limb indicating the need for limb amputation in the&#xD;
             short term.&#xD;
&#xD;
          -  Evidence of osteomyelitis in the ischemic extremity.&#xD;
&#xD;
          -  Current or previous history of neoplasia.&#xD;
&#xD;
          -  Unstable angina, recent stroke or other medical condition that contraindicate&#xD;
             anesthesia for bone marrow aspiration.&#xD;
&#xD;
          -  Proliferative retinopathy.&#xD;
&#xD;
          -  Debilitating disease with a life span less than one year.&#xD;
&#xD;
          -  Myelofibrosis, myelodysplasia or other diseases that affect the bone marrow.&#xD;
&#xD;
          -  Use of alcohol in excess of twice-daily doses or history of illicit drug use.&#xD;
&#xD;
          -  Need for continuous high doses of drug therapy with steroids (more than 7.5 mg/day).&#xD;
&#xD;
          -  Positivity for HIV or syphilis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Brofman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontifícia Universidade Católica do Paraná</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pontifícia Universidade Católica do Paraná</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80215-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2013</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pontifícia Universidade Católica do Paraná</investigator_affiliation>
    <investigator_full_name>Alexandra Cristina Senegaglia</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Lowe extremity ischemia</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Neoangiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Gangrene</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

